Silo Pharma Seeks Shareholder Approval for Massive 37.5x Increase in Authorized Common Stock
SILO sits 85% above its 52-week low of $3.315 on light trading volume (0.4× avg).
Summary
Silo Pharma is seeking shareholder approval to increase its authorized common stock from 6.67 million to 250 million shares, enabling significant future capital raises for acquisitions and operations.
Key Events · Corporate Governance and Compliance · SILO
-
Proposed Authorized Share Increase
Shareholders will vote on increasing authorized common stock from 6,666,667 to 250,000,000 shares.
-
Significant Potential Dilution
If all authorized shares were issued, dilution would be over 22,000% relative to current outstanding shares.
-
Purpose for Capital Raising
The company intends to use the additional shares to raise equity capital for acquisitions of in vitro fertilization clinics and general corporate purposes to reach cash flow breakeven.
-
Annual Meeting Scheduled
The proposals will be voted on at the 2026 Annual Meeting of Shareholders on August 14, 2026.
Analysis · SILO · Life Sciences
Silo Pharma is asking shareholders to approve an amendment to its Articles of Incorporation to increase the number of authorized common shares from 6,666,667 to 250,000,000. This represents a potential increase of over 22,000% in shares relative to the current outstanding count of 1,128,610. The company states this is necessary to raise equity capital for business objectives, including acquisitions of in vitro fertilization clinics to reach cash flow breakeven. This authorization, if approved, provides the company with significant flexibility for future capital raises, but also introduces a substantial overhang of potential dilution for existing shareholders.
At the time of this filing, SILO was trading at $6.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6M. The 52-week trading range was $3.32 to $15.15. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.